These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 15124331)

  • 21. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 22. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 23. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 24. Integrating intellectual property within the organizational social structure.
    Daizadeh I
    Nat Biotechnol; 2003 May; 21(5):573-5. PubMed ID: 12721578
    [No Abstract]   [Full Text] [Related]  

  • 25. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 26. Slow to execute: why not-for-profit hospitals lag behind American business.
    White TW
    Healthc Leadersh Manag Rep; 2001 Sep; 9(9):1-4. PubMed ID: 11702436
    [No Abstract]   [Full Text] [Related]  

  • 27. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 28. Gray marketing of pharmaceuticals.
    Chaudhry PE; Walsh MG
    J Health Care Mark; 1995; 15(3):18-22. PubMed ID: 10172516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When turnaround management works.
    Di Primio A
    J Bus Strategy; 1988; 9(1):61-4. PubMed ID: 10313826
    [No Abstract]   [Full Text] [Related]  

  • 30. BIO marches to Congress with growth package in hand.
    Carey K
    Nat Biotechnol; 2011 Sep; 29(9):776-7. PubMed ID: 21904306
    [No Abstract]   [Full Text] [Related]  

  • 31. First Rounders Podcast: Stanley Crooke.
    Nat Biotechnol; 2015 Sep; 33(9):897. PubMed ID: 26349902
    [No Abstract]   [Full Text] [Related]  

  • 32. Ichan the spoiler.
    Creswell J
    Fortune; 2005 Mar; 151(6):195-6, 198. PubMed ID: 15782883
    [No Abstract]   [Full Text] [Related]  

  • 33. Strategic planning. Growing into your future.
    Elliott S
    Trustee; 2000 Jun; 53(6):27-8. PubMed ID: 11806368
    [No Abstract]   [Full Text] [Related]  

  • 34. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 35. The science-business tango. Interview by Mari Paul.
    Hirth P
    Nat Biotechnol; 2006 Aug; 24(8):1035-6. PubMed ID: 16900153
    [No Abstract]   [Full Text] [Related]  

  • 36. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 37. Demise of the life science company begins.
    Niiler E
    Nat Biotechnol; 2000 Jan; 18(1):14. PubMed ID: 10625374
    [No Abstract]   [Full Text] [Related]  

  • 38. Best of both worlds.
    Smaglik P
    Nature; 2003 Dec; 426(6967):706-7. PubMed ID: 14668875
    [No Abstract]   [Full Text] [Related]  

  • 39. Researchers cut loose as Pfizer and Merck shutter European sites.
    Subbaraman N
    Nat Biotechnol; 2011 Apr; 29(4):299-300. PubMed ID: 21478836
    [No Abstract]   [Full Text] [Related]  

  • 40. What can Johnson & Johnson do to remain a giant in the health care industry?
    Carter T
    J Hosp Mark Public Relations; 2002; 14(1):93-103. PubMed ID: 12569997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.